These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23805398)

  • 1. Review of Gardasil.
    Harper DM; Vierthaler SL; Santee JA
    J Vaccines Vaccin; 2010 Nov; 1(107):. PubMed ID: 23805398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papillomavirus vaccines.
    Schmiedeskamp MR; Kockler DR
    Ann Pharmacother; 2006; 40(7-8):1344-52. PubMed ID: 16849621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies.
    Harper DM; Williams KB
    Discov Med; 2010 Jul; 10(50):7-17. PubMed ID: 20670593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cervical cancer: screening and prevention.
    Behtash N; Mehrdad N
    Asian Pac J Cancer Prev; 2006; 7(4):683-6. PubMed ID: 17250453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cervical cancer prevention: the impact of HPV vaccination].
    Monsonégo J
    Gynecol Obstet Fertil; 2006 Mar; 34(3):189-201. PubMed ID: 16529969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    Westra TA; Stirbu-Wagner I; Dorsman S; Tutuhatunewa ED; de Vrij EL; Nijman HW; Daemen T; Wilschut JC; Postma MJ
    BMC Infect Dis; 2013 Feb; 13():75. PubMed ID: 23390964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HPV vaccination programs have not been shown to be cost-effective in countries with comprehensive Pap screening and surgery.
    Wilyman J
    Infect Agent Cancer; 2013 Jun; 8(1):21. PubMed ID: 23758803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
    Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
    Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil).
    Govan VA
    Ther Clin Risk Manag; 2008 Feb; 4(1):65-70. PubMed ID: 18728721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors.
    Damm O; Nocon M; Roll S; Vauth C; Willich S; Greiner W
    GMS Health Technol Assess; 2009 Mar; 5():Doc04. PubMed ID: 21289891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anal dysplasia screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2007; 7(4):1-43. PubMed ID: 23074504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevention of cervical cancer (II): prophylactic HPV vaccination, current knowledge, practical procedures and new issues].
    Monsonego J
    Presse Med; 2007 Apr; 36(4 Pt 2):640-66. PubMed ID: 17350792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
    McCormack PL; Joura EA
    Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus, cervical cancer, and the vaccines.
    Tovar JM; Bazaldua OV; Vargas L; Reile E
    Postgrad Med; 2008 Jul; 120(2):79-84. PubMed ID: 18654072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus.
    Kash N; Lee MA; Kollipara R; Downing C; Guidry J; Tyring SK
    J Clin Med; 2015 Apr; 4(4):614-33. PubMed ID: 26239350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
    Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
    Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF
    Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gardasil-9: A global survey of projected efficacy.
    Zhai L; Tumban E
    Antiviral Res; 2016 Jun; 130():101-9. PubMed ID: 27040313
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.